Goldman Sachs Sticks to Their Sell Rating for FIGS (FIGS)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Roach is a 4-star analyst with an average return of 6.0% and a 51.63% success rate. Roach covers the Consumer Cyclical sector, focusing on stocks such as Kontoor Brands, Kohl's, and Nike.
The word on The Street in general, suggests a Hold analyst consensus rating for FIGS with a $4.90 average price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
2 hours ago
- CNBC
Goldman Sachs' Salveen Richter on Sarepta's ongoing troubles, opportunities in biotech
Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Squawk Box' to discuss the troubles facing Sarepta and its muscular dystrophy drug Elevidys, state of the biotech sector, what to expect on earnings next week, and more.
Yahoo
2 hours ago
- Yahoo
Piper Sandler Says These 2 Stocks Are Top Picks for the Second Half of 2025
There's no magic formula for picking winning stocks, but having the right guide can make all the difference. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That's where Wall Street's analysts come in. With a front-row seat to market movements and company performance, these pros make it their business to spot standout opportunities. And now, with 2025 beyond the halfway mark, it's the perfect moment to check in on the names they're backing for the rest of the year. Watching the current mid-year situation for Piper Sandler, analyst Jason Bednar lays out the attributes he's looking for in top-pick stocks, writing: 'Key themes across our top names include confidence we have in management's execution against guidance and Street estimates for the coming quarters, balance sheet flexibility that is good and/or improving, and risk/reward that skews favorably based on a combination of catalysts and valuation on shares.' With this in mind, we dug into the TipRanks database to get the broader Wall Street take on two of his top picks, and both are rated Buy, with the potential for double-digit gains. Let's break down the names, the numbers, and what makes them stand out. STERIS (STE) First up on our list, STERIS, is a medical technology (medtech) company. STERIS was founded in 1985 and is based in Ohio; the company got its start specializing in low-temperature liquid sterilization of surgical instruments. Today, the company is a global leader in infection prevention, offering a line of products and services designed to support patient care for a better medical outcome. To achieve that goal, STERIS offers a diverse array of products, including medical consumables such as detergents, endoscopy accessories, and barrier devices. On the service side, the company can install and maintain medical equipment, provide sterilization for medical devices, repair medical instruments and scopes, and provide lab testing. Finally, STERIS can also provide its customers with larger-scale capital equipment, such as surgical tables, automated endoscope reprocessors, and even integrated connectivity solutions for today's high-tech operating rooms. STERIS offers its products under several categories, and reports its revenue under the categories Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The largest of these is Healthcare, which accounted for approximately 73% of the company's total revenue in its last reported quarter. That quarter was fiscal 4Q25 (March quarter), for which STERIS reported $1.5 billion in total revenue. This was up 4% year-over-year and beat the forecast by $30 million. At the bottom line, STERIS realized a quarterly adjusted net income of $2.74 per diluted share, a figure that was 14 cents above expectations. The company's free cash flow rose year-over-year, from $620.3 million to $787.2 million in the current report. Checking in with Piper Sandler, we find that analyst Bednar wastes no time in explaining why this stock made his list. Bednar writes, 'Why is it a top idea? STE is a model of consistency, posting MSD+ top-line and HSD/LDD bottom-line growth in six of the past seven years, underpinned by healthy end markets, disciplined capital allocation and a focus on lean operations. For medtech investors, that's a model deserving of a premium valuation. Growth in the high-margin AST segment has improved sequentially for six consecutive quarters, and the segment growth outlook has gotten cleaner of late… Balance sheet leverage is as light as it's been in several years (~1.3x net leverage), and this Board/mgmt team have a bias to accretive M&A.' Based on this stance, Bednar rates STE shares as Overweight (i.e., Buy), with a $280 price target to suggest a one-year upside potential of 24%. (To watch Bednar's track record, click here) The consensus rating here is a Moderate Buy, based on 5 Buy and 2 Hold ratings. Meanwhile, the $270.33 average target price indicates room for an upside of 20% by this time next year. (See STE stock forecast) Merit Medical Systems (MMSI) The second stock we're looking at here is another medtech, Merit Medical Systems. This firm, based in the suburbs of Salt Lake City, Utah, is known as a developer, manufacturer, and distributor of medical devices, particularly devices used in interventional, diagnostic, and therapeutic procedures. Merit Medical's product lines feature proprietary designs, and are intended to be disposable; they are most often used in the fields of cardiology, radiology, oncology, critical care, and endoscopy. Merit Medical has a global footprint, with some 7,300 employees, including an international team of marketers and clinical support that totals more than 800. The company is recognized as a global leader in disposable medical tools. The company boasts a market cap of $5 billion. Earlier this month, Merit suffered a sharp blow to its stock price, falling as much as 10% on July 16, after a regulatory disclosure. That disclosure involved a warning letter from the FDA, regarding issues of quality control at one of the company's manufacturing facilities. These types of warnings are not uncommon from regulators, but in this case, the timing is a problem – Merit is currently expanding its product lines, and a warning letter of this type may have a stronger impact than usual. The company has already stated that it is working in concert with the FDA to address the issues raised in the letter. Looking at Merit's product lines, we find that the company has its hands in a wide range of categories. To give a small list: the company produces hemostasis accessories, dialysis equipment, safety kits, infusion systems, pulmonary stents, GI dilation balloons, and blood sampling devices. The company also provides educational resources, including on-demand courses and recorded webinars, to provide tutorials on its various equipment lines and products. We can also note that on May 6 this year, Merit announced its latest regulatory approval, with Health Canada's approval of Merit's Wrapsody Cell-Impermeable Endoprosthesis. The company is also undergoing a leadership change, and current CEO Fred Lampropoulos will be stepping down in October. His place will be taken by Martha Aronson, effective on October 3. Mr. Lampropoulos will remain as Chairman of the Board. Merit's last quarterly report covered 1Q25, and in that quarter the company had revenues of $355.4 million. This was up 10% year-over-year and beat the forecast by $2.8 million. The non-GAAP EPS figure, of 86 cents, beat expectations by 11 cents per share. Checking in again with Piper Sandler's Bednar, we see the analyst weighing various pros and cons here, writing, 'MMSI has demonstrated durable and consistent growth and management has been superb in managing investor expectations over the past 4+ years… Management already positively pre-announced 2Q and detailed CEO transitions plans, but we also see an EPS beat and guidance raise as being in order. The WRAPSODY reimbursement strategy will be a focal point after failing to secure TPT on management's previously announced timeline, but we're optimistic the developments to date will result in this being more of a short delay for securing TPT.' Summing up, Bednar sees this medtech as a solid choice, and advises investors to buy in, saying of MMSI, 'Longer-term, we believe an extension of what's been a solid execution story should keep MMSI one of the premium mid-cap assets in medtech.' These comments are complemented by an Overweight (i.e., Buy) rating, and a price target which, at $110, points toward a one-year gain of 29%. This stock has earned a Strong Buy from the Street's analysts, a consensus based on 10 recent reviews that split 9 to 1 in favor of Buy over Hold. The shares are currently trading for $85.06 and the average price target of $108.80 implies the stock will gain 28% in the next 12 months. (See MMSI stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
Time Business News
4 hours ago
- Time Business News
How Is AI Used in Investment Management?
The world of investment management is changing fast. Nowadays, AI is playing a significant part in the making of decisions, risk management and portfolio building. Big US based companies such as BlackRock, JPMorgan Chase, Goldman Sachs, and Morgan Stanley are making their way. They've already launched their own AI platforms — like BlackRock's Aladdin and JPMorgan's LLM suite — to help make smarter, faster choices. The demand for a reliable FinTech software development company such as Hidden Brains is all-time high. These tools aren't just for big players. More firms are now turning to AI to manage the growing flood of data and stay ahead in the market. In this article, we'll look at how AI is being used in investment management and why it matters for the future. Managing investments today isn't easy. The amount of financial data out there is just too much for people to handle alone. That's where AI is involved. It can swiftly identify patterns, trends and risks that a human might not catch. Data then enables investors to make better, more informed decisions without having to drown in information. AI is already becoming a must-have tool. In 2024, the US AI in the asset management market was valued at $1.65 billion. It's expected to reach a huge $14.17 billion by 2034, growing at a fast pace of 23.99% CAGR over the next decade. Right now, over 90% of US asset managers are already using some form of AI. They even depend on it in areas such as portfolio optimization, risk management and even communications with the clients. In the most basic explanation, AI assists the investment worker to work smart rather than hard. AI isn't just a buzz word in the investment world. It's a tool used in many different ways to make work easier, faster and smarter. From constructing portfolios to identifying risks, AI is supporting companies to be a step ahead in the rate of technology marketplace. Partnering with a FinTech software development company can help you implement artificial intelligence in your asset management solution and make accurate decisions. Let's dive in a little bit more deeply on how AI is being used. A major advantage of AI is that it enhances portfolio management. Artificial intelligence tools are capable of analyzing masses of market data, tendencies, and even the world news to determine the most efficient investment decisions. This is not all speculation, AI employs insights in real time to assist companies in the development of portfolios which compare to various levels of risk and financial objectives. Some companies also work with robo-advisors (Betterment or Wealthfront). The tools save time and limit the number of human errors since they automatically form and tinker investment strategies according to the needs of each client. Another field where AI is leaving a significant impression is risk management. Markets are highly dynamic and they can shift within a second and AI assists in identifying the possible threats before becoming actual issues. AI can be used to analyze past information and current trends by using predictive analytics to alert a firm about potential losses. This allows investment managers to have ample time to change tactics and not to wander into avoidable risks. Artificial intelligence is also useful in real-time monitoring of market fluctuations, thus enabling companies to be ready. When it comes to trading, AI works quicker than any human could possibly do. AI algorithms equipped can understand market signals and historical data to make a smart trade in less than a second. These tools are used to execute trades extremely fast and large in volume, they help companies stay competitive. AI also takes away emotions in trading choices. It is based on facts and trends and not on fear or guesswork that can lead to more accurate results down the line. Preserving investments is as important as increasing investments. AI contributes by monitoring abnormal trends in financial dealings that leads to possible fraud. It can detect suspicious activities in a manner much quicker than conventional systems. AI is equally assisting companies to be current in the compliance regulations. Regulations are repeatedly modified, and with the use of AI tools, updates are tracked so that corporations did not commit a mistake that might result in fines or a court case. It is not only in money management that AI is playing a role since it is also assisting companies get to know their customers better. AI can service clients more personally by observation of their behavioral patterns and preferences. It is easy to see how AI can enhance the experience of clients, whether by providing custom investment advice or, more proactively, by informing them of changes. Clients who can feel understood and supported are more inclined to be loyal to the firm, having the trust. The use of AI in the management of investments is no longer a matter of theory, but it is already being practiced in several of the largest financial establishments. These companies are demonstrating how AI can generate true value both among institutional customers and retail investors. So, what better way to do that than let's take a closer look? The Aladdin investment platform introduced by BlackRock is among the most sophisticated AI-driven investment platforms in the world. Not only BlackRock but other financial institutions use this to monitor risk, portfolio analysis and data-driven investment decisions. Aladdin combines massive amounts of data with machine learning to help investors see potential risks before they happen. It's like having a smart assistant that continuously watches over your investments — quietly, efficiently, and 24/7. JPMorgan Chase has already spent a lot on AI and large language models (LLMs) to improve their approach to trading strategies to customer service. They use AI to analyze market sentiment, predict economic shifts, and even write earnings summaries. The goal? To help their teams — and clients- move faster with better insights. JPMorgan's LLM suite reflects how seriously the bank is taking AI's role in the future of finance. Its Next Best Action platform does not leave behind Morgan Stanley. This AI-assisted working tool enables financial advisors to provide more customized suggestions to their respective customers. When taking into consideration the economic history, aspirations, and even the market transformations of each particular client, the platform can presuppose what an advisor should discuss or present next, which makes the experience seem much more natural and initiative-oriented. Artificial intelligence is rapidly transforming to be a game-changer in investment management. Whether it implies smarter and faster decision-making in companies such as BlackRock and JPMorgan or the possibility to provide common investors with access to automated robots (robo-advisors), AI is not only the future, but the present as well. The rapid adoption of AI in financial institutions, such as banks, is significantly impacting the overall industry and transforming the nature of their business. The technology is only getting bigger; hence, even more personalized, data-led, and efficient investment strategies can be anticipated just about everywhere. TIME BUSINESS NEWS
